General Information |
Clinical trials phase |
Phase 1 |
Start date (estimated) |
2020-09-11 |
Clinical feature |
Label |
head and neck cancer |
Link |
http://purl.obolibrary.org/obo/DOID_11934 |
Description |
An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx. |
|
Administrative Information |
ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCT2033200116 |
Other study identifiers |
Name |
jRCT2033200116 |
Description |
Japan Registry of Clinical Trials (jRCT) |
|
Source weblink |
https://jrct.niph.go.jp/en-latest-detail/jRCT2033200116 |
Public contact |
Email |
t-fujiwara@chiba-u.jp |
Public email |
t-fujiwara@chiba-u.jp |
First name |
Tadami |
Last name |
Fujiwara |
Phone |
+81-43-222-7171 |
City |
Chiba |
Country |
|
Address freetext |
Chiba University Hospital Dept. of Otorhinolaryngology, Head and Neck Surgery, Chiba University Hospital 1-8-1 Inohana, Chuo-ku, Chiba, 260-0856 Japan |
|
Cells |
Which differentiated cell type is used |
Label |
natural killer cell |
Link |
http://purl.obolibrary.org/obo/CL_0000623 |
Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
Recruitment Status |
Recruiting |
Estimated number of participants |
9 |
Contact institutions/departments |
|